Amyloid fibril protein nomenclature: 2012 recommendations from the Nomenclature Committee of the International Society of Amyloidosis

Jean D. Sipe, Merrill Benson, Joel N. Buxbaum, Shu Ichi Ikeda, Giampaolo Merlini, Maria J M Saraiva, Per Westermark

Research output: Contribution to journalArticle

179 Citations (Scopus)

Abstract

The Nomenclature Committee of the International Society of Amyloidosis (ISA) met during the XIIIth International Symposium, May 610, 2012, Groningen, The Netherlands, to formulate recommendations on amyloid fibril protein nomenclature and to consider newly identified candidate amyloid fibril proteins for inclusion in the ISA Amyloid Fibril Protein Nomenclature List. The need to promote utilization of consistent and up to date terminology for both fibril chemistry and clinical classification of the resultant disease syndrome was emphasized. Amyloid fibril nomenclature is based on the chemical identity of the amyloid fibril forming protein; clinical classification of the amyloidosis should be as well. Although the importance of fibril chemistry to the disease process has been recognized for more than 40 years, to this day the literature contains clinical and histochemical designations that were used when the chemical diversity of amyloid diseases was poorly understood. Thus, the continued use of disease classifications such as familial amyloid neuropathy and familial amyloid cardiomyopathy generates confusion. An amyloid fibril protein is defined as follows: the protein must occur in body tissue deposits and exhibit both affinity for Congo red and green birefringence when Congo red stained deposits are viewed by polarization microscopy. Furthermore, the chemical identity of the protein must have been unambiguously characterized by protein sequence analysis when so is practically possible. Thus, in nearly all cases, it is insufficient to demonstrate mutation in the gene of a candidate amyloid protein; the protein itself must be identified as an amyloid fibril protein. Current ISA Amyloid Fibril Protein Nomenclature Lists of 30 human and 10 animal fibril proteins are provided together with a list of inclusion bodies that, although intracellular, exhibit some or all of the properties of the mainly extracellular amyloid fibrils.

Original languageEnglish
Pages (from-to)167-170
Number of pages4
JournalAmyloid
Volume19
Issue number4
DOIs
StatePublished - Dec 2012

Fingerprint

Amyloidogenic Proteins
Amyloidosis
Amyloid
Terminology
Congo Red
Proteins
Familial Amyloid Neuropathies
Polarization Microscopy
Birefringence
Inclusion Bodies
Protein Sequence Analysis
Cardiomyopathies
Netherlands

Keywords

  • Amyloid fibril
  • Amyloid protein
  • Amyloidosis
  • Hereditary
  • Inclusion body
  • Nomenclature

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Amyloid fibril protein nomenclature : 2012 recommendations from the Nomenclature Committee of the International Society of Amyloidosis. / Sipe, Jean D.; Benson, Merrill; Buxbaum, Joel N.; Ikeda, Shu Ichi; Merlini, Giampaolo; Saraiva, Maria J M; Westermark, Per.

In: Amyloid, Vol. 19, No. 4, 12.2012, p. 167-170.

Research output: Contribution to journalArticle

Sipe, Jean D. ; Benson, Merrill ; Buxbaum, Joel N. ; Ikeda, Shu Ichi ; Merlini, Giampaolo ; Saraiva, Maria J M ; Westermark, Per. / Amyloid fibril protein nomenclature : 2012 recommendations from the Nomenclature Committee of the International Society of Amyloidosis. In: Amyloid. 2012 ; Vol. 19, No. 4. pp. 167-170.
@article{cd73b19a9982401592bd9703d11d35dd,
title = "Amyloid fibril protein nomenclature: 2012 recommendations from the Nomenclature Committee of the International Society of Amyloidosis",
abstract = "The Nomenclature Committee of the International Society of Amyloidosis (ISA) met during the XIIIth International Symposium, May 610, 2012, Groningen, The Netherlands, to formulate recommendations on amyloid fibril protein nomenclature and to consider newly identified candidate amyloid fibril proteins for inclusion in the ISA Amyloid Fibril Protein Nomenclature List. The need to promote utilization of consistent and up to date terminology for both fibril chemistry and clinical classification of the resultant disease syndrome was emphasized. Amyloid fibril nomenclature is based on the chemical identity of the amyloid fibril forming protein; clinical classification of the amyloidosis should be as well. Although the importance of fibril chemistry to the disease process has been recognized for more than 40 years, to this day the literature contains clinical and histochemical designations that were used when the chemical diversity of amyloid diseases was poorly understood. Thus, the continued use of disease classifications such as familial amyloid neuropathy and familial amyloid cardiomyopathy generates confusion. An amyloid fibril protein is defined as follows: the protein must occur in body tissue deposits and exhibit both affinity for Congo red and green birefringence when Congo red stained deposits are viewed by polarization microscopy. Furthermore, the chemical identity of the protein must have been unambiguously characterized by protein sequence analysis when so is practically possible. Thus, in nearly all cases, it is insufficient to demonstrate mutation in the gene of a candidate amyloid protein; the protein itself must be identified as an amyloid fibril protein. Current ISA Amyloid Fibril Protein Nomenclature Lists of 30 human and 10 animal fibril proteins are provided together with a list of inclusion bodies that, although intracellular, exhibit some or all of the properties of the mainly extracellular amyloid fibrils.",
keywords = "Amyloid fibril, Amyloid protein, Amyloidosis, Hereditary, Inclusion body, Nomenclature",
author = "Sipe, {Jean D.} and Merrill Benson and Buxbaum, {Joel N.} and Ikeda, {Shu Ichi} and Giampaolo Merlini and Saraiva, {Maria J M} and Per Westermark",
year = "2012",
month = "12",
doi = "10.3109/13506129.2012.734345",
language = "English",
volume = "19",
pages = "167--170",
journal = "Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis",
issn = "1350-6129",
publisher = "Informa Healthcare",
number = "4",

}

TY - JOUR

T1 - Amyloid fibril protein nomenclature

T2 - 2012 recommendations from the Nomenclature Committee of the International Society of Amyloidosis

AU - Sipe, Jean D.

AU - Benson, Merrill

AU - Buxbaum, Joel N.

AU - Ikeda, Shu Ichi

AU - Merlini, Giampaolo

AU - Saraiva, Maria J M

AU - Westermark, Per

PY - 2012/12

Y1 - 2012/12

N2 - The Nomenclature Committee of the International Society of Amyloidosis (ISA) met during the XIIIth International Symposium, May 610, 2012, Groningen, The Netherlands, to formulate recommendations on amyloid fibril protein nomenclature and to consider newly identified candidate amyloid fibril proteins for inclusion in the ISA Amyloid Fibril Protein Nomenclature List. The need to promote utilization of consistent and up to date terminology for both fibril chemistry and clinical classification of the resultant disease syndrome was emphasized. Amyloid fibril nomenclature is based on the chemical identity of the amyloid fibril forming protein; clinical classification of the amyloidosis should be as well. Although the importance of fibril chemistry to the disease process has been recognized for more than 40 years, to this day the literature contains clinical and histochemical designations that were used when the chemical diversity of amyloid diseases was poorly understood. Thus, the continued use of disease classifications such as familial amyloid neuropathy and familial amyloid cardiomyopathy generates confusion. An amyloid fibril protein is defined as follows: the protein must occur in body tissue deposits and exhibit both affinity for Congo red and green birefringence when Congo red stained deposits are viewed by polarization microscopy. Furthermore, the chemical identity of the protein must have been unambiguously characterized by protein sequence analysis when so is practically possible. Thus, in nearly all cases, it is insufficient to demonstrate mutation in the gene of a candidate amyloid protein; the protein itself must be identified as an amyloid fibril protein. Current ISA Amyloid Fibril Protein Nomenclature Lists of 30 human and 10 animal fibril proteins are provided together with a list of inclusion bodies that, although intracellular, exhibit some or all of the properties of the mainly extracellular amyloid fibrils.

AB - The Nomenclature Committee of the International Society of Amyloidosis (ISA) met during the XIIIth International Symposium, May 610, 2012, Groningen, The Netherlands, to formulate recommendations on amyloid fibril protein nomenclature and to consider newly identified candidate amyloid fibril proteins for inclusion in the ISA Amyloid Fibril Protein Nomenclature List. The need to promote utilization of consistent and up to date terminology for both fibril chemistry and clinical classification of the resultant disease syndrome was emphasized. Amyloid fibril nomenclature is based on the chemical identity of the amyloid fibril forming protein; clinical classification of the amyloidosis should be as well. Although the importance of fibril chemistry to the disease process has been recognized for more than 40 years, to this day the literature contains clinical and histochemical designations that were used when the chemical diversity of amyloid diseases was poorly understood. Thus, the continued use of disease classifications such as familial amyloid neuropathy and familial amyloid cardiomyopathy generates confusion. An amyloid fibril protein is defined as follows: the protein must occur in body tissue deposits and exhibit both affinity for Congo red and green birefringence when Congo red stained deposits are viewed by polarization microscopy. Furthermore, the chemical identity of the protein must have been unambiguously characterized by protein sequence analysis when so is practically possible. Thus, in nearly all cases, it is insufficient to demonstrate mutation in the gene of a candidate amyloid protein; the protein itself must be identified as an amyloid fibril protein. Current ISA Amyloid Fibril Protein Nomenclature Lists of 30 human and 10 animal fibril proteins are provided together with a list of inclusion bodies that, although intracellular, exhibit some or all of the properties of the mainly extracellular amyloid fibrils.

KW - Amyloid fibril

KW - Amyloid protein

KW - Amyloidosis

KW - Hereditary

KW - Inclusion body

KW - Nomenclature

UR - http://www.scopus.com/inward/record.url?scp=84868374880&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868374880&partnerID=8YFLogxK

U2 - 10.3109/13506129.2012.734345

DO - 10.3109/13506129.2012.734345

M3 - Article

C2 - 23113696

AN - SCOPUS:84868374880

VL - 19

SP - 167

EP - 170

JO - Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis

JF - Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis

SN - 1350-6129

IS - 4

ER -